Introduction {#S0001}
============

The deregulation of metabolic homeostasis leads to metabolic disorders such as fatty liver disease, obesity and diabetes.[@CIT0001],[@CIT0002] The liver functions as a major metabolic regulator for maintaining metabolic homeostasis, allowing extrahepatic tissues such as adipose and muscle to function normally under overnutrition or starvation.[@CIT0003]--[@CIT0005] During starvation, the liver coordinates a series of metabolic adaptations to maintain the energy balance of the system and provide adequate nutrients to key organs, tissues and cells.[@CIT0006],[@CIT0007] These regulatory mechanisms in the liver include supplying glucose to the circulation, initially from hepatic glycogen and then by gluconeogenesis produced from other non-carbohydrate materials.[@CIT0008] In a sustained fasting state, ketones are synthesized by the liver to provide an energy source to replace glucose for high-oxygen consuming tissues.[@CIT0009],[@CIT0010] Fatty acid oxidation is considered to be critical for providing ATP and NADP to facilitate glycogenesis and acetyl-CoA for ketogenesis.[@CIT0011],[@CIT0012] Accumulating studies have revealed that many molecules participate in regulating hepatic metabolism during fasting or other physiological states, including sterol regulatory element-binding protein-1c (SREBP-1c),[@CIT0013] peroxisome proliferator-activated receptor-alpha,[@CIT0005],[@CIT0014] glucocorticoid receptor , cAMP responsive element binding protein 1, and CCAAT/enhancer binding protein beta.[@CIT0015] It would be valuable to discover novel mediator(s) to further understand the regulation of liver function upon starvation stress.

NOD-like receptor protein 3 (NLRP3)-inflammasomes, composed of NLRP3, adapter protein ACS and pro-caspase 1, is an important regulator of the activation of caspase1 and the maturation of IL1β. It can be activated by multiple mediators, including metabolic disturbance.[@CIT0016],[@CIT0017] Previous studies mainly discussed the function of NLRP3 in macrophages where it is abundantly expressed. During the last few years, researchers indicated that NLRP3 inflammasome is closely related to the pathogenesis of most acute and chronic liver injuries,[@CIT0018],[@CIT0019] increased expression of hepatic NLRP3, ACS and caspase-1 accompanies with liver inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, which suggests a strong link between NLRP3 inflammasomes and hepatic dysfunction. Although NLRP3 inflammasome is highly expressed in liver, the regulatory mechanism of NLRP3 inflammasome on lipid synthesis, fatty acid oxidation, and transport in hepatocytes remains unknown.

In the present study, we discovered that the NLRP3 is involved in the regulation of fasting-induced hepatic steatosis and hepatic lipogenesis in hepatocytes. Its inhibitor MCC950 restrained SREBP-1c expression and transcriptional activation and reduced lipogenesis-associated gene expression, which suggests that NLRP3 is a critical regulator of metabolic homeostasis upon starvation stress.

Materials and methods {#S0002}
=====================

Animals and treatment {#S0002-S2001}
---------------------

Male wild-type C57BL/6J littermates (8-weeks-old) were randomly divided into three groups: fed, fasted, and refed, as described previously.[@CIT0020] The fed group was fed a normal chow diet; the fasted group was fasted for 24 hrs; and the refed group was fasted for 24 hrs, followed by 6 hrs of refeeding prior to the end of the experiment. MCC950 or vehicle was administered intraperitoneally at a dose of 10 mg/kg prior to diet deprivation or refeeding. The animals were housed in standard cages at 22°C in a 12/12-hrs light/dark cycle. When the mice were sacrificed, blood samples were collected, and tissues were taken rapidly and fixed or stored in liquid nitrogen. All animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethical Committee of Huazhong University of Science and Technology.

Western blot analysis {#S0002-S2002}
---------------------

Tissue samples were lysed at 4°C with RIPA buffer containing protease and phosphatase inhibitors. Forty micrograms of protein, as measured by a standard bicinchoninic acid assay (BSA) kit, were loaded onto 10% SDS-polyacrylamide gels for electrophoresis. Then, proteins were transferred to polyvinylidene difluoride membranes and blocked with 5% dry milk for 2 hrs at room temperature. Next, the membranes were probed with primary antibodies overnight at 4°C and incubated with secondary horseradish peroxidase antibodies for 1 hrs. Subsequently, the proteins were detected with a Bio-Rad (Hercules, CA, USA) imaging system. The following antibodies were used: β-tubulin (1:1,000 dilution, ab6046, Abcam), NLRP3 (1:1,000 dilution, 15101, Cell Signaling Technology), Caspase1 (1:1,000 dilution, NBP1-45433, Novus), IL1β (1:1,000 dilution, 12242, Cell Signaling Technology), FASN (1:1,000 dilution, 3180, Cell Signaling Technology), ACC1 (1:1,000 dilution, 4190, Cell Signaling Technology), and SREBP-1c (1:1,000 dilution, ab28481, Abcam).

ELISA {#S0002-S2003}
-----

The concentration of IL1β in plasma was measured by ELISA kits (MLB00C, R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. Absorbance at 450 nm was measured using a microplate reader (Thermo Fisher Scientific), and the 450 nm absorbance values were corrected by subtracting the reading at 570 nm.

Measurement of plasma and hepatic metabolites {#S0002-S2004}
---------------------------------------------

Blood glucose concentrations were determined using a glucometer. Mouse plasma insulin was measured with an ultrasensitive mouse insulin ELISA kit (Millipore, Billerica, MA, USA). Liver lipid contents were extracted as previously described;[@CIT0021] Plasma and liver triglyceride and cholesterol levels were detected using commercial assay kits \[290--63,701 and 294--65,801 for triglyceride and cholesterol, respectively; Wako, Osaka, Japan\] according to the manufacturer's instructions.

Oil red O staining {#S0002-S2005}
------------------

Livers were immersed in OCT and kept at −80°C until use. After 5 mins of drying, frozen sections were incubated with oil red O, washed with 60% isopropanol, and counterstained with Mayer's hematoxylin and saturated lithium carbonate. The images were captured on a light microscope.

Quantitative real-time qPCR {#S0002-S2006}
---------------------------

Tissue samples were homogenized with TRIzol reagent (Invitrogen, USA); total RNA was isolated and treated with RNase-free DNase to remove genomic DNA, and then reverse transcribed into cDNA by using a PrimeScript RT reagent kit (Takara, China). Real-time qPCR was performed using an ABI 7500 real-time PCR system and SYBR Green PCR Master Mix (Takara, China) in duplicate. StepOne Software v2.3 (Applied Biosystems, Waltham, MA, USA) was used to analyze the results with the 2^−△△CT^-method after normalization to β-actin levels (18s was used to determine that β-actin does not change between groups; [Figure S1](#SF0001)).

The primers applied to real-time qPCR were as follows:

18S-Forward: 5'-TTGACGGAAGGGCACCACCAG-3ʹ; 18S-Reverse: 5ʹ-GCACCACCACCCACGGAATCG-3ʹ; β-actin-Forward: 5ʹ-AACAGTCCGCCTAGAAGCAC-3ʹ; β-actin-Reverse: 5ʹ-CGTTGACATCCGTAAAGACC-3ʹ; IL1β-Forward: 5ʹ-GAAATGCCACCTTTTGACAGTG-3ʹ; IL1β-Reverse: 5ʹ-TGGATGCTCTCATCAGGACAG-3ʹ; SREBP1c-Forward: 5ʹ-GCAGCCACCATCTAGCCTG-3ʹ; SREBP1c-Reverse: 5ʹ-CAGCAGTGAGTCTGCCTTGAT-3ʹ; FASN-Forward: 5ʹ-GGAGGTGGTGATAGCCGGTAT-3ʹ; FASN-Reverse: 5ʹ-TGGGTAATCCATAGAGCCCAG-3ʹ; ACC1-Forward: 5ʹ-ATGGGCGGAATGGTCTCTTTC-3ʹ; ACC1-Reverse: 5ʹ-TGGGGACCTTGTCTTCATCAT-3ʹ; ACOX-Forward: 5ʹ-TAACTTCCTCACTCGAAGCCA-3ʹ; 18S-Reverse: 5ʹ-AGTTCCATGACCCATCTCTGTC-3ʹ; CPT1a-Forward: 5ʹ-TGGCATCATCACTGGTGTGTT-3ʹ; 18S-Reverse: 5ʹ-GTCTAGGGTCCGATTGATCTTTG-3ʹ; MCAD-Forward: 5ʹ-AGGGTTTAGTTTTGAGTTGACGG-3ʹ; 18S-Reverse: 5ʹ-CCCCGCTTTTGTCATATTCCG-3ʹ; CD36-Forward: 5ʹ-ATGGGCTGTGATCGGAACTG-3ʹ; 18S-Reverse: 5ʹ-GTCTTCCCAATAAGCATGTCTCC-3ʹ; FABP1-Forward: 5ʹ-ATGAACTTCTCCGGCAAGTACC-3ʹ; 18S-Reverse: 5ʹ-CTGACACCCCCTTGATGTCC-3ʹ; DGAT1-Forward: 5ʹ-TCCGTCCAGGGTGGTAGTG-3ʹ; 18S-Reverse: 5ʹ-TGAACAAAGAATCTTGCAGACGA-3ʹ;

Cell line and culture {#S0002-S2007}
---------------------

HepaRG cells (HepaRGC10) were purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA) and cultured as described in the manufacturer's instructions. Cells were cultured at 37°C with 5% CO~2~ in a humidified atmosphere. After 24 hrs of serum starvation, the cells were treated as described below.

Luciferase reporter assays {#S0002-S2008}
--------------------------

A human SREBP-1c promoter-driven luciferase plasmid encoding a 5ʹ-flanking fragment of the SREBP-1c (−1005/+24) promoter was described previously.[@CIT0022] Transfections in HepaRG cells were performed in triplicate in 24-well plates. After overnight starvation, 250 ng of SREBP-1c promoter reporter plasmids or empty vector, together with pRL-TK encoding Renilla luciferase, were co-transfected by using Lipofectamine 2000. After transfection, cells were treated with 250 µM BSA-conjugated palmitic acid (P5585, Sigma, St Louis, MO, USA) or vehicle, in the presence or absence of MCC950. Luciferase activity was measured 24 hrs later using a Dual-Luciferase Reporter Assay System (Promega, Fitchburg, WI, USA), and normalized to Renilla luciferase activity.

Chromatin immunoprecipitation (ChIP) {#S0002-S2009}
------------------------------------

Chromatin immunoprecipitation (ChIP) experiments were performed exactly as described previously.[@CIT0023],[@CIT0024] Liver tissues were subjected to cross-linking with 1% formaldehyde before the preparation of nuclear extracts. Chromatin-SREBP-1c complexes were immunoprecipitated with anti-SREBP-1c or rabbit IgG (Cell Signaling Technology) by incubation at 4°C overnight on a rocking platform, and then were incubated with the beads from the ChIP kit at 4°C for 2 hrs with gentle rocking. After washing sufficiently with the washing buffer, the complexes were eluted with the elution buffer from the beads, and the extracted DNA from the final step was quantified by PCR to amplify the FASN and ACC1 promoters. The primers were as follows: mouse FASN: forward, 5′-TCACATCAGGGGACAGTTAG-3′; reverse, 5′-TAAGCAAATAGAGAACTCCC-3′; mouse ACC1: forward, 5′-GTCCCGCCTCCTCCAGT-3′; reverse, 5′-GACTTCAGAGCCCACCGAC-3′; The raw Ct values of the ChIP samples were divided by the Ct values of the relevant input samples, and the values were presented as the percentage of the input values (% input).

Statistical analysis {#S0002-S2010}
--------------------

GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analysis. Band densitometry of the Western blot images was quantified with ImageJ Software. All data are presented as the mean ± SEM. Comparisons between two groups were conducted by Student's *t* test, and one-way ANOVA was used to assess the statistical significance among multiple groups. *P*\<0.05 was considered statistically significant. All data are representative of three independent experiments.

Results {#S0003}
=======

The NLRP3-inflammasome is inhibited by nutrient deprivation and triggered by refeeding {#S0003-S2001}
--------------------------------------------------------------------------------------

To investigate whether the NLRP3-inflammasome is involved in fasting-induced hepatic steatosis, we measured hepatic NLRP3, pro-casp1, active casp1, pro-IL1β and active IL1β expression levels. We found that NLRP3, active casp1 and IL1β were decreased after 24 hrs of fasting and recovered upon refeeding in mice ([Figure 1A](#F0001){ref-type="fig"}). Meanwhile, the mRNA and plasma levels of IL1β showed a parallel change ([Figure 1B-C](#F0001){ref-type="fig"}). These data indicate the potential role of the NLRP3-inflammasome in fasting-induced hepatic steatosis.Figure 1NLRP3-inflammasome is inhibited by nutrient deprivation and triggered by refeeding. (**A**) Western blot and densitometric analysis for NLRP3, active-casp1 and IL1β in liver of fed, fasted, and refed mice, with n=6 per group. (**B**) Relative mRNA levels of IL1β in liver of fed, fasted, and refed mice, with *n*=8 per group. (**C**) ELISA assay detected plasma levels of IL1β in fasting and refeeding mice, with *n*=8 per group. \* *P*˂0.05, \*\* *P*˂0.01, \*\*\* *P*˂0.001 and \*\*\*\* *P*˂0.0001 compared to the fed group; ^\#^ *P*˂0.05, ^\#\#^ *P*˂0.01 and ^\#\#\#^*P*˂0.001 compared to the fasted group.

MCC950 effectively inhibits IL1β secretion and ameliorates fasting-induced hepatic lipid deposition {#S0003-S2002}
---------------------------------------------------------------------------------------------------

To explore whether inhibition of the NLRP3-inflammasome plays a role in fasting-induced lipid instability, we treated mice with MCC950 prior to diet deprivation or refeeding. As shown in [Figure 2A](#F0002){ref-type="fig"}, the circulating IL1β levels were increased by refeeding and were significantly decreased by MCC950 compared to that of vehicle. MCC950 administration increased blood glucose levels both in fasted mice and refed mice, while without having an impact on plasma insulin levels ([Figure 2B](#F0002){ref-type="fig"}). In the liver, fasting-induced lipid deposition was significantly ameliorated by administration of MCC950, as confirmed by the macroscopic appearance of the liver and Oil red O staining ([Figure 2C](#F0002){ref-type="fig"} and [D](#F0002){ref-type="fig"}). Further quantitative analysis revealed that MCC950 reduced the triglyceride content in liver but not in plasma compared to that of the vehicle ([Figure 2E](#F0002){ref-type="fig"}). However, there were no significant changes in cholesterol levels between the different groups ([Figure 2F](#F0002){ref-type="fig"}). The results show that the inhibition of NLRP3 largely reduced hepatic lipid deposition.Figure 2MCC950 effectively inhibits IL1β secretion and ameliorates fasting-induced hepatic lipid deposition. (**A**) Plasma levels of IL1β were decreased by MCC950 administration. (**B**) Blood glucose and plasma insulin levels in vehicle or MCC950 treated mice after fasting for 24 hrs or followed by *n*6 h-refeeding. (**C**) Hepatic macroscopic appearance of different groups. (**D**) Representative Oil red O staining of frozen liver sections. Hepatic and plasma triglyceride, the scale bar is 100 um. (**E**) and cholesterol (**F**) levels in vehicle or MCC950 treated mice after fasting or refeeding. n=8 per group. \*\* *P*˂0.01 compared to the fasted group treated with vehicle, ^\#^ *P*˂0.05 and ^\#\#^ *P*˂0.01 compared to the vehicle group under the same diet treatment.

MCC950 alters the expression of key genes related to lipogenesis in the liver {#S0003-S2003}
-----------------------------------------------------------------------------

To examine the latent mechanism of MCC950 on hepatic steatosis, we examined metabolic-associated genes in the liver. Real-time qPCR revealed that lipogenesis-related genes (eg, SREBP-1c, FASN, and ACC1) were suppressed in the MCC950 group compared to those of the vehicle group both in fasted and refed mice ([Figure 3A](#F0003){ref-type="fig"}), while fatty acid utilization-related genes (eg, ACOX, CPT1a, and MCAD) were unaltered by MCC950 treatment ([Figure 3B](#F0003){ref-type="fig"}). However, genes related to fatty acid transportation (eg, CD36, and FABP1) or esterification (eg, DGAT1) showed no consistent changes either in starvation or refeeding ([Figure 3C-D](#F0003){ref-type="fig"}). Therefore, the improvement of MCC950 on fasting-induced hepatic steatosis is mainly through the amelioration of intrahepatic lipogenesis.Figure 3MCC950 alters the expression of key genes related to lipogenesis in the liver. (**A**) Hepatic lipogenesis-related genes such as SREBP-1c, FASN, and ACC1 were acutely induced by refeeding and inhibited in MCC950 treated mice. (**B-D**) Effects of MCC950 treatment on fatty acid β-oxidation (ACOX, CPT1α, and MCAD), transportation (CD36, and FABP1), and esterification (DGAT1) compared to that of vehicle-treated group. n=8 per group. \* *P*˂0.05, \*\* *P*˂0.01, \*\*\* *P*˂0.001, and \*\*\*\* *P*˂0.0001 compared to the fasted group treated with vehicle, ^\#^ *P*˂0.05 and ^\#\#\#\#^ *P*˂0.0001 compared to the vehicle group under the same diet treatment.

MCC950 suppressed SREBP-1c expression and its regulatory effect on lipogenesis {#S0003-S2004}
------------------------------------------------------------------------------

To further delineate the mechanisms responsible for the phenotype in MCC950 challenged mice, the levels of proteins involved in lipogenesis were examined. As shown in [Figure 4A-B](#F0004){ref-type="fig"}, the nuclear form and precursor of SREBP-1c were increased upon refeeding, while MCC950 treatment remarkably inhibited the expression of the nuclear form and precursor of SREBP-1c both in fasted and refed state. Accordantly, the target genes of SREBP-1c (eg, ACC1, and FASN) were also attenuated by MCC950 treatment ([Figure S2](#SF0002)). In vitro, NLRP3-inflammasome can be activated by PA and inhibited by MCC950 ([Figure S3](#SF0003)). To further confirm the role of MCC950 on SREBP-1c, we detected an effect of MCC950 on SREBP-1c transcriptional activity which was induced by PA in HepaRG cells using a luciferase reporter gene assay. As shown in [Figure 4C](#F0004){ref-type="fig"}, SREBP-1c promoter activity was inhibited by MCC950 in a dose-dependent manner. In addition, the binding of SREBP-1c to its target genes (eg, FASN and ACC1) was slightly decreased during starvation, while prominently reduced after refeeding, as analyzed by the ChIP assay in the liver tissues of mice ([Figure 4D](#F0004){ref-type="fig"}). Collectively, these results indicate that MCC950 inhibits SREBP-1c expression and transcriptional activity, suppresses lipogenesis-related genes expression, thus ameliorates nutrient instability-induced steatosis.Figure 4MCC950 inhibits SREBP-1c expression and prevents its regulation on downstream target genes. (**A**) Metabolism-related signaling pathway was detected by Western blot in fasted and refed mice challenged with MCC950 or vehicle, with β-tubulin as a loading control. (**B**) Quantitative results of the protein levels of mature or precursors SREBP-1c, Casp1, IL1β. \* *P*˂0.05, \*\* *P*˂0.01 and \*\*\* *P*˂0.001 compared to the fasted group treated with vehicle, ^\#^ *P*˂0.05 and ^\#\#\#^*P*˂0.001 compared to the vehicle group under the same diet treatment. (**C**) Normalized activities of the luciferase reporters analyzing the effect of MCC950 on SREBP-1c promoter activation which was induced by PA in HepaRG cells. ^&^ *P*\<0.05 and ^&&^ *P*\<0.01. (**D**) Chromatin immunoprecipitation (ChIP) assay using chromatin isolated from livers of mice after fasting or refeeding. Nuclear extracts were immunoprecipitated with an anti-SREBP-1c antibody, and purified DNA was subjected to qPCR by specific primers located at the promoter region of mouse FASN and ACC1. ^\#^ *P*˂0.05 compared to the refed group treated with vehicle.

Discussion {#S0004}
==========

Mammals have developed multiple mechanisms for accommodating changes in the environment, such as changes in food availability.[@CIT0025] Liver, as the central organ in regulating metabolism,[@CIT0004] plays an irreplaceable role in maintaining nutrient stability during starvation and refeeding, and also is subjected to various nutrient stress,[@CIT0026] such as lipotoxic, inflammation.[@CIT0027] NLRP3 is a member of the NLR family, activation of the NLRP3-inflammasome increases caspase1 activation and IL1β production, which indicate that NLRP3 is an important regulator of the inflammatory response. Recent studies show that activation of the NLRP3-inflammasome is associated with metabolic dysfunction,[@CIT0028] which provides us with new insight into whether and how NLRP3 can regulate lipid metabolism.

The NLRP3-inflammasome was suppressed during starvation, but was rescued after refeeding, along with the activation of caspase1 and increased maturation of IL1β. When we intraperitoneally injected the mice with the selective NLRP3 inhibitor MCC950, we observed the amelioration of the fasting-induced liver lipid accumulation, which demonstrated a novel role of NLRP3 in the regulation of fasting-induced hepatic steatosis.

Additionally, we examined several pathways associated with lipid metabolism (lipogenesis, fatty acid oxidation, lipid transportation and esterification) and their effector molecules. MCC950 significantly inhibited genes expression related to lipogenesis, while the genes involved in fatty acid oxidation, including ACOX, CPT1α and MCAD showed no obvious changes. This finding suggested that the protective effects of MCC950 in fasting-induced hepatic steatosis and the accompanying metabolic system changes are mainly due to the inhibition of lipogenesis.

SREBP-1c is a master regulator of genes involved in lipogenesis and plays an important regulatory role in lipid metabolism. Further exploring the underlying the mechanism of MCC950 in the regulation of hepatic lipogenesis, we detected a reduction of mature form and precursors of SREBP-1c in the liver when injected with MCC950. We stimulated lipid deposition in vitro using a HepaRG cell line that was treated with palmitic acid[@CIT0029],[@CIT0030] and challenged with MCC950, which resulted in the concentration-dependent suppression of SREBP-1c promoter activity in the luciferase assay. Chromatin immunoprecipitation (ChIP) assays of liver tissue also showed that MCC950 remarkably attenuated the transcription of its downstream target genes (FASN and ACC1).

The most important finding of our work is that NLRP3-inflammasome accelerated lipogenesis in hepatocytes, for its inhibitor MCC950 suppressed the transcription activity of SREBP-1c and its target genes FASN and ACC1. Intraperitoneal injection of MCC950 not only affected the activity of NLRP3-inflammasome in hepatocytes, but also inhibited the inflammatory response of kupffer cells (KCs; macrophages in the liver), which is a limitation of our study. Although we demonstrated that MCC950 reduced SREBP-1c transcription while inhibiting NLRP3-inflammasome activation, we do not know whether KCs are involved in this regulatory relationship. The crosstalk between KCs and hepatocytes is worth exploring, and we will do further researches in this field.

In conclusion, our findings establish a new role for NLRP3 and its inhibitor MCC950 in the regulation of lipogenesis and metabolic disorders after exposure to starvation or refeeding. The inhibition of NLRP3 could ameliorate lipid accumulation, liver injury and dyslipidemia, which may prospect its importance in regulating the adaptive responses of the liver upon starvation stress, and provide therapeutic value.
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Figure S1β-Actin does not differ between groups. Real-time qPCR indicated that housekeeping gene 18S and β-actin do not differ between groups. n=8 per group. Figure S2Inhibition of NLRP3-inflammasome reduced the protein level of lipogenesis-related genes. Densitometric analysis for FASN and ACC1 in fasted and refed mice treated with MCC950 or vehicle. \* *P*˂0.05, and \*\* *P*˂0.01 compared to the fasted group treated with vehicle, ^\#^ *P*˂0.05, ^\#\#^ *P*˂0.01 and ^\#\#\#^ *P*˂0.001 compared to the vehicle group under the same diet treatment. Figure S3The NLRP3-inflammasome can be activated by PA treatment and inhibited by MCC950 in a concentration-dependent way in HepaRG cell line. Western blot of NLRP3 in HepaRG indicated that PA treatment activates NLRP3 inflammasome, which could be suppressed by MCC950.
